A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018–19 influenza season

To evaluate the relative vaccine effectiveness (rVE) against influenza-related hospitalizations/emergency room (ER) visits, office and cardio-respiratory disease (CRD)-related hospitalizations/ER visits compare all-cause costs associated with two vaccines specifically indicated for older adults (?65 years), adjuvanted (aTIV) high-dose trivalent influenza (TIV-HD), 2018–19 season. A retrospective analysis of was conducted using claims hospital data in United States. For clinical evaluations, adjusted analyses were following inverse probability treatment weighting (IPTW) to control selection bias. Poisson regression used estimate rVE any CRD-related visits. economic evaluation, bias through 1:1 propensity score matching (PSM). All-cause hospitalizations/ER, physician pharmacy generalized estimating equation (GEE) models. After IPTW regression, aTIV (n = 561,315) slightly more effective reducing compared TIV-HD 1,672,779) (6.6%; 95% CI: 2.8–10.3%). statistically comparable (2.0%; ?3.7%-7.3%) preventing but CRD (2.6%; 2.0–3.2%). In PSM-adjusted cohorts 561,243 pairs), GEE adjustments, predicted mean annualized total per patient similar between (US$9676 vs. US$9625 US$18.74 US$17.28, respectively; both p > 0.05). Finally, lower as ($1.75 vs $1.85; < 0.0001). During season, hospitalization/ER among people aged ? 65 TIV-HD. event this population.